Lv21
190 积分 2023-12-27 加入
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
8天前
已完结
Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitors
9天前
已完结
Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitors
9天前
已完结
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
12天前
已完结
Contactin-4 suppresses antitumor T cell responses by engaging amyloid precursor protein
12天前
已完结
Expanding Conjugate Space of RNAi Therapeutics: Ligand at the 3′ End of the Antisense Strand Achieves Uncompromised In Vivo Potency and Efficacy and Reveals Interactions with the Argonaute-2 PAZ Domain
12天前
已完结
Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial
19天前
已完结
Atroposelective Negishi Coupling Optimization Guided by Multivariate Linear Regression Analysis: Asymmetric Synthesis of KRAS G12C Covalent Inhibitor GDC-6036
20天前
已完结
Garsorasib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial
25天前
已关闭
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
1个月前
已完结
皖公网安备34019202002308
